Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
NCT00003022 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003022 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer |
| Official title | Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma |
| Intervention type | Radiation |
| Interventions | iodine I 131 monoclonal antibody 3F8 |
| Start date | Apr 1, 1997 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: